Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Halt Medical's Tulip RFVTA probe granted Canadian approval for treatment of uterine fibroids

Halt Medical, Inc. announced today that it has been approved to market the Tulip™ Radiofrequency Volumetric Thermal Ablation (RFVTA) probe in Canada. "The license we just received from Health Canada brings us an important step closer to our goal of making our uterine sparing procedure available to the millions of women in North America who suffer with uterine fibroids", said Russ DeLonzor, President and COO of Halt Medical.

19 Oct 2010

Researchers propose Nintendo Wii gaming to control gestational diabetes in women

Many women have trouble finding time to exercise in their busy lifestyles. That's especially true for pregnant women who live in northern climates such as Canada, where the weather can limit outdoor activity during winter months every year. But exercise is critical to managing gestational diabetes, a growing problem that occurs in 2 to 9 per cent of pregnancies.

14 Oct 2010

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

The Focused Ultrasound Surgery Foundation is hosting the 2nd International Symposium on MR-guided Focused Ultrasound in Chantilly, Virginia from October 17-20. Leading researchers and clinicians from around the world will gather at the three-day scientific conference to present and discuss the latest advancements in one of the most revolutionary and promising areas of therapeutic medicine.

6 Oct 2010

Merit Medical Systems acquires BioSphere Medical

Merit Medical Systems, Inc. today announced the completion of its acquisition of BioSphere Medical, Inc., a leading developer and marketer of embolotherapeutic products for the treatment of uterine fibroids, hypervascularized tumors, and arteriovenous malformations.

13 Sep 2010

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients.

31 Aug 2010

First time use of ExAblate MR Guided Focused Ultrasound System for prostate cancer treatment

Elbit Imaging Ltd. that it's subsidiary, InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients.

31 Aug 2010

New Halt System procedure for non-cancerous fibroid treatment

A new device manufactured by Northern California-based Halt Medical recently received FDA 510K clearance using a radio-frequency energy system to treat soft tissues. Fully qualified doctors insert the Halt System into targeted fibroids under ultrasound guidance. This procedure targets the core of the fibroid, by cauterizing the blood flow that feeds the fibroid, which decreases fibroid size and subsequent discomfort.

24 Aug 2010

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

Due to overwhelming response from researchers, a second round of abstract submissions for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound will open on Monday, August 23, 2010, nine days earlier than previously announced. The submission deadline will be moved forward to Monday, September 6, 2010.

19 Aug 2010

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

PregLem, the Swiss specialty biopharmaceutical company focused on women's reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

11 Aug 2010

Repros granted IRB approval to commence low dose Proellex study

Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.

22 Jul 2010

SIR and 41 international societies issue first global statement defining interventional radiology

The Society of Interventional Radiology, with the support of 41 international societies representing 10,000 interventional radiology doctors, has issued the first global statement defining interventional radiology-one designed to benefit medical treatment for individuals. The statement addresses the evolution, impact and future direction of this minimally invasive specialty, emphasizing the worldwide availability of this specialized medical care.

8 Jul 2010

UPA: An effective non-invasive treatment for fibroids can help maintain fertility in women

A new, effective, non-surgical treatment for uterine fibroids can help women with this condition maintain their fertility, an American scientist told the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome today (Wednesday).

30 Jun 2010

International symposium to highlight current and future applications of MR-guided ultrasound

Leading research and clinical experts from around the world are scheduled to speak at the 2nd International Symposium for MR-guided Focused Ultrasound, which will be held October 17 to 20 in the Washington, D.C. area.

From Elekta 29 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

FDA clears Halt 2000GI Electrosurgical System for soft tissue ablation

Halt Medical, Inc., today announced that the U.S. Food and Drug Administration (FDA) has cleared the Halt 2000GI™ Electrosurgical System for soft tissue ablation using radiofrequency energy. "This clearance to market is a major milestone for our customers, employees and investors," said Russ DeLonzor, President and Chief Operating Officer.

16 Jun 2010

Repros receives FDA confirmation on lifting of full clinical hold on Proellex

Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.

11 Jun 2010

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

4 Jun 2010

European Society of Human Reproduction and Embryology 2010 meeting set for June 27-30 in Rome, Italy

New research findings from fertility experts from Europe, the Americas, Asia & Australasia

31 May 2010

PCA-Rx represents next generation of chelation technology for ASD patients

According to the Center for Disease Control, autism has risen to an epidemic rate of 1 in 100 in the U.S., up from 1 in 150 in 2007. While controversy looms regarding its cause, many parents of autistic children believe a correlation exists with toxin accumulation. To give autism spectrum disorder sufferers a natural alternative to chelation therapy, Maxam Nutraceutics has introduced PCA-Rx.

28 May 2010

MicroStockProfit.com: BSMD's total worldwide revenues for first-quarter 2010 decline 2%

MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 May 2010

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Halt Medical's Tulip RFVTA probe granted Canadian approval for treatment of uterine fibroids

Researchers propose Nintendo Wii gaming to control gestational diabetes in women

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

Merit Medical Systems acquires BioSphere Medical

InSightec's ExAblate Robotic Acoustic Surgery system used for prostate cancer treatment

First time use of ExAblate MR Guided Focused Ultrasound System for prostate cancer treatment

New Halt System procedure for non-cancerous fibroid treatment

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

Repros granted IRB approval to commence low dose Proellex study

SIR and 41 international societies issue first global statement defining interventional radiology

UPA: An effective non-invasive treatment for fibroids can help maintain fertility in women

International symposium to highlight current and future applications of MR-guided ultrasound

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

FDA clears Halt 2000GI Electrosurgical System for soft tissue ablation

Repros receives FDA confirmation on lifting of full clinical hold on Proellex

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

European Society of Human Reproduction and Embryology 2010 meeting set for June 27-30 in Rome, Italy

PCA-Rx represents next generation of chelation technology for ASD patients

MicroStockProfit.com: BSMD's total worldwide revenues for first-quarter 2010 decline 2%

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in